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Background: Data on therapeutic interventions following deliberate self harm (DSH) in patients with
treatment-resistant depression (TRD) are very scant and there is no unanimous consensus on the best
pharmacological option for these patients. There is some evidence that lithium treatment might be effective in
reducing the risk of completed suicide in adult patients with unipolar affective disorders, however no clear cut
results have been found so far. The primary aim of the present study is to assess whether adding lithium to
standard therapy is an effective treatment strategy to reduce the risk of suicidal behaviour in long term treatment
of people with TRD and previous history of DSH.
Methods/Design: We will carry out a randomised, parallel group, assessor-blinded superiority clinical trial. Adults
with a diagnosis of major depression, an episode of DSH in the previous 12 months and inadequate response to at
least two antidepressants given sequentially at an adequate dose for an adequate time for the current depressive
episode will be allocated to add lithium to current therapy (intervention arm) or not (control arm). Following
randomisation, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Suicide
completion and acts of DSH during the 12 months of follow-up will constitute the composite primary outcome. To
preserve outcome assessor blindness, an independent adjudicating committee, blind to treatment allocation, will
anonymously review all outcome events.
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Discussion: The results of this study should indicate whether lithium treatment is associated with lower risk of
completed suicide and DSH in adult patients with treatment resistant unipolar depression, who recently attempted
suicide.
Trial registration: ClinicalTrials.gov identifier: NCT00927550
Keywords: Randomised controlled trial, Lithium, Suicide, Deliberate self harm, Mortality, Depression, Treatment
resistant, AntidepressantBackground
International guidelines usually define treatment-
resistant depression (TRD) as an episode of major
depression which fails to respond to two or more anti-
depressants given sequentially at an adequate dose and
for an adequate time [1-3]. Interestingly, there is no
unanimous consensus on the best pharmacological
option in these patients: recommendations include
switching to a different antidepressant, combining two
antidepressants and adding another drug, like lithium,
atypical antipsychotics, thyroid hormone, lamotrigine
or pindolol [4]. Moreover, an important clinical feature
frequently associated to such a difficult to treat popula-
tion is that in TRD suicidal thoughts are common.
They represent alarming psychopathological symptoms,
[5] which may lead to deliberate self harm (DSH), sui-
cide attempts and, in up to 10% of cases, to completed
suicides [6].
Unfortunately, data on therapeutic interventions fol-
lowing non-fatal suicidal behaviour in patients with
TRD are very scant. Hawton and colleagues carried out
a Cochrane review to evaluate the effect of specific
treatments for patients with depression and history of
DSH [7,8]. Only three studies were found and the sum-
mary odds ratio (OR) indicated only a non-significant
trend towards reduced repetition of DSH for anti-
depressant therapy compared with placebo (OR 0.83,
95% confidence interval (CI) 0.47 to 1.48). In addition
to antidepressants, a possible beneficial effect in terms
of suicidal behaviour has been suggested for lithium
[9]. In a systematic review and meta-analysis of 32 trials
recruiting patients with mood disorders, lithium was
more effective than placebo on the risk of suicide, DSH
and all-cause mortality, even though these differences
were not statistically significant. Some limitations of
this systematic review should be borne in mind: the in-
cluded trials were not primarily designed to measure
this outcome and heterogeneous patient populations
were enrolled, including unipolar and bipolar patients.
Another meta-analysis focused specifically on patients
with recurrent, unipolar major depressive disorder and
suggested for lithium an antisuicidal effect similar in
magnitude to that found in bipolar disorders [10].
However, the major limitation of this analysis is thatnon-randomised studies were included in the analysis
and this may have led to biased results.
In 2008, the results of a randomised, placebo-
controlled trial focusing on the suicide preventive ef-
fects of lithium in patients with suicidal behaviour were
published [11]. In this multi-centre trial (the SUPLI
Study), patients with a recent history of a suicide
attempt were treated double blind with lithium or pla-
cebo and followed up for 12 months. Of 167 patients
included in the analysis, only 75% had a diagnosis of
major depression: 20% of the whole sample had a diag-
nosis of adjustment disorder and 5% was suffering from
dysthymia or related depressive disorders [12]. Survival
analysis showed no significant difference of suicidal acts
between lithium and placebo-treated individuals (ad-
justed hazard ratio 0.52; 95% CI 0.18 to 1.43). However,
post hoc analysis revealed that all completed suicides
had occurred in the placebo group accounting for a sig-
nificant difference in incidence rates (p=0.049).
Lauterbach and colleagues have suggested that lithium
may specifically have suicide preventive effects because
in their RCT all of the observed suicides occurred in
the placebo group and none in the lithium group. How-
ever, the overall number of events was very small (all
three suicides in the placebo group) and the lithium-
treated individuals were at a higher risk as a result of
the significant difference in number of previous suicide
attempts which is the most reliable predictor for further
suicidal behaviour [13]. Moreover, it also seems that the
potential antisuicidal effect of lithium was independent
from its mood-stabilising effects. Speculations about
possible mechanisms of action involving the central
serotonin system have been suggested, because lithium
is thought to facilitate 5-HT neurotransmission [14] or
may exert its antisuicidal effects influencing aggressive
and impulsive traits that are linked to serotonergic dys-
function and also involved in the mediation of suicidal
behaviour [15,16]. Evidence from this study suggested
lithium treatment to be effective in reducing the risk of
completed suicide in adult patients with unipolar
affective disorders, however no clear cut results were
found in terms of DSH (or suicidality) and the hetero-
geneity in terms of diagnosis of the recruited sample
might have acted as an important confounder.
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whether adding lithium to standard therapy is an ef-
fective treatment strategy to reduce the risk of suicidal
behaviour in long term treatment of people with TRD
and previous history of DSH. Secondary aims of the
study are: (a) to assess whether adding lithium has a
specific impact in improving depressive symptoms;
(b) to assess the long term tolerability profile of the
lithium-augmentation strategy.
Methods/Design
In a multi-centre, 12-month, superiority trial, we will
randomise patients with TRD and history of DSH to (i)
add lithium to usual treatment (add-on lithium strategy)
or (ii) avoid lithium in usual treatment (without-lithium
strategy). To be as close as possible to clinical practice,
patients and clinicians will not be blind to treatments
provided during the trial. However, to limit the potential
bias introduced by lack of blindness, an independent
adjudicating committee, blind to treatment allocation,
will validate the events that will constitute the primary
outcome. Patients will be assessed at baseline before
randomisation and then every month after random allo-
cation until the completion of the 12-month follow-up.
All phases of the trial will be recorded following the
CONSORT statement [17,18].
Study population
Patients will be recruited in Italy. Community psychiatric
services agreeing to take part to the study will be asked
to recruit consecutive patients meeting the inclusion/
exclusion criteria. Patients will be referred either from
psychiatric wards or from community-based outpatient
clinics. A total number of 50–60 psychiatric services
will be involved. During the routine medical consult-
ation relevant patients will be informed of and offered
participation in the trial. If the patient agrees to partici-
pate in the trial, an appointment will be made for com-
pletion of relevant rating scales and questionnaires.
Patients will be then randomly allocated to lithium
plus usual treatment (either pharmacological or non-
pharmacological) or to usual treatment alone.
To take part in the trial all patients must meet all of
the inclusion criteria and none of the exclusion criteria,
as follows:
Inclusion criteria
(a)Diagnosis of major depression (clinical diagnosis,
guided by DSM-IV criteria).
(b)An episode of DSH in the previous 12 months.
(c) Inadequate response to at least two antidepressants
given sequentially at an adequate dose for an
adequate time for the current depressive episode.(d)Uncertainty about which treatment arm would be
best for the participant.
(e)Age 18 or above.
(f ) To sign written informed consent.
Exclusion criteria
(a)A primary diagnosis of any concurrent Axis I
disorder (according to DSM-IV criteria) other than
major depression (by contrast, any concurrent
DSM-IV Axis II disorder will not constitute an
exclusion criterion).
(b)Previous exposure to lithium associated with lack of
efficacy or adverse reactions.
(c)Clinical conditions contraindicating lithium (i.e.,
thyroid or kidney disease/abnormalities).
(d)Pregnant/lactating women and women of
childbearing potential not practicing a reliable
method of contraception.
Interventions
Lithium is currently marketed in Italy for the treatment
of major depression and it will be prescribed according
to Italian usual care. Patients allocated to lithium will be
administered an oral starting dose ranging between 150
and 300 milligrams (according to clinical judgement).
Suggested final oral dose will have to achieve plasma
levels of 0.4 to 1.0 mmol/L. Clinicians will be free of in-
creasing or decreasing the dose according to clinical sta-
tus and circumstances. Dose changes will be recorded.
Following randomisation, treatment is to be taken daily
for 1 year unless some clear reason to stop develops. Pa-
tients allocated to the lithium arm will receive usual
pharmacological and non-pharmacological treatment as
clinically indicated. Any other pharmacological treat-
ment will be allowed.
Patients allocated to the control arm will receive usual
pharmacological and non-pharmacological treatment as
clinically indicated. Patients allocated to the control arm
will not be allowed to receive lithium. Any other
pharmacological treatment will be allowed.
Routine care outside the trial continues as usual. Du-
ring the study, participants will be seen as often as cli-
nically indicated with no extra visits required for the
trial.
Baseline and follow up assessments
Before entering the study, patients will be asked to provide
informed consent to participate. The following informa-
tion will be collected at baseline: sociodemographic and
clinical characteristics, diagnosis according to the Mini
Neuropsychiatry Interview (MINI) [19], laboratory and
electrocardiography (ECG) parameters, severity of illness
according to the Quick Inventory Depression Scale
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to have good psychometric properties [21]. Detailed infor-
mation will be gathered on previous DSH acts, as well.
Follow-up data will be obtained each month after
random allocation using an electronic form, as follows:
any death or DSH, lithium oral dose and plasma level
(if applicable), concomitant drug treatments, QIDS
scores, adverse events and information on laboratory
and ECG parameters.
Random allocation procedure
Patients will be randomly assigned to one of the two treat-
ment groups with an equal probability of assignment to
each treatment (allocation ratio 1:1). A centralised ran-
domisation procedure will be employed. The trial biosta-
tistician will prepare the sequence of treatments randomly
permuted in blocks of unequal size. The allocation will be
stratified by presence or absence of Axis II diagnosis
(patients with unipolar major depression AND perso-
nality disorder vs patients with unipolar major depres-
sion WITHOUT personality disorder) because this
variable may have an impact on the study outcomes (see
Discussion).The randomisation schedule will be generated
using nQuery Advisor, release 7.0. Recruiting physicians
will contact an administrator at the World Health Orga-
nisation Collaborative Centre for Research and Training
in Mental Health and Service Evaluation of the University
of Verona who will access a computerised system that will
provide, after information on the enrolled participant is
entered and inclusion criteria are verified, the patient's
identification number and the allocated treatment.
Outcomes
Suicide completion and acts of DSH during the 12 months
of follow-up will constitute the composite primary out-
come. The term “suicide” is defined as an act with a fatal
outcome, deliberately initiated and performed by the
person with the knowledge or expectation of its fatal
outcome. DSH is defined as intentional self-poisoning or
self-injury, irrespective of motivation, as the intention to
end life may be absent or present to a variable degree
[7,8]. To preserve outcome assessor blindness, an inde-
pendent adjudicating committee (three clinical psychia-
trists, with no links to the study and blind to treatment
allocation) will anonymously review all deaths and all
hazardous acts reported during the 12 months of follow-
up by the treating clinicians. The committee will have the
role of identifying, among deaths, the cases of suicide, and
among hazardous acts those that constitute acts of DSH.
Only the cases of suicide and those of DSH validated by
the committee will constitute the primary outcome.
As secondary outcomes, we will consider number of
events (acts of DSH), number of suicides and all-cause
mortality, change in severity of depressive symptomsfrom baseline to endpoint and adverse reactions during
the 12 months of follow-up.
Power analysis and sample size calculation
When we first drafted the study protocol, the sample
size calculation was based on data from three anti-
depressant clinical trials that employed completed and
attempted suicide as the primary endpoint [7,8] (for
details, see clinicaltrials.gov, ClinicalTrials.gov identifier:
NCT00927550). However, the most recently published
evidence has shown that the event rate of completed
and attempted suicide in patients with unipolar, recur-
rent depression (with or without Axis II diagnosis) is
higher than expected and can be more than 35% at 12
months [22,23]. According to this data, hypothesising
that lithium augmentation (experimental group) would
show a clinically significant advantage by producing an
event rate of 10% [7,8], a sample size of 210 patients
(105 in each group) achieves 80% power for a 0.05 level
of two-sided log-rank test (31 events expected).
Statistical analysis
The statistical analysis will be masked, i.e. the trial bio-
statistician will be blinded to the treatment groups until
the analysis has been completed. All analyses will be
performed using Stata/SE, Release 11.1. Data lock will
occur at 12 months, when data will be available for all
participants. The pattern of missing values will be ex-
plored and interactions between treatment group and
non-completers/completers will be examined with respect
to demographic variables and baseline disease assessment.
The intention-to-treat (ITT) population, consisting of
all subject randomly assigned to the competitive treat-
ment strategies, will be used for the analysis of primary
and secondary outcomes. Patients with missing values
and patients lost during follow-up will contribute to the
analysis of the primary and secondary outcomes only for
the time during which data are available (censoring).
Missing values in depressive symptom ratings will be im-
puted using the last observation carried forward (LOCF)
approach: depressive ratings will be carried forward from
the last available assessment to the 12-month follow up
assessment. Additionally, patients in each arm will be al-
ways analysed according to the corresponding treatment
group’s allocation at baseline.
In order to check the consistency of this ITT approach,
the primary outcome will then be analysed using a per-
protocol (PP) approach. The analysis of the PP population
will be used for confirmatory purposes only. If less than
5% of patients switch from the allocated treatment to
the competitive treatment, the PP analysis will not be
performed.
Kaplan-Meier estimates for the time from randomised
treatment assignment until the first event that constitutes
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ment’s effect, and log-rank test will be performed to test
for differences. A Cox proportional hazard model will be
used to explore the effect of possible confounding or
interaction factors. Gender and age will be included into
the model regardless of statistical significance criteria. The
proportional hazard assumption of the effects will be
tested. No interim analysis is planned for this trial.
Time from randomised treatment assignment until all-
cause mortality during the 12 months of follow-up will
be analysed through a log-rank test for difference in sur-
vival between the two groups. The same method will be
applied for the following secondary outcomes: suicide
mortality, deliberate self-harm. Multivariate analyses will
be performed to explore the possible role of prognostic
factors on outcomes.
Change in severity of depressive symptoms from base-
line to 12 months will be analysed as a continuous va-
riable and as a dichotomous variables, where individuals
showing an improvement of al least 50% will be consi-
dered treatment responders. Change in severity of illness
at 12-months will be compared between the two groups
of treatment through appropriate statistical methods for
repeated measurements (paired t-test or McNemar non
parametric test according to the variables distribution).
The number of events/outcomes of interest (suicide or
DSH) will be compared between the two groups of treat-
ment through the chi-square test (or the Fisher’s exact
test when appropriate). When possible, a multivariate
analysis will be performed through a Poisson regression
model with a robust error variance.
The proportion of patients with adverse reactions du-
ring the study will be compared between the two groups
of treatment through the chi-square test (or the Fisher’s
exact test when appropriate).
Data management
All study data will be entered in a computerised data-
base and stored by the World Health Organisation Col-
laborative Centre for Research and Training in Mental
Health and Service Evaluation of the University of
Verona. The correctness and consistency of the data will
be ensured by the double-entry technique and by a set
of electronic and manual edit checks. In accordance
with the Declaration of Helsinki, patients’ confidentiality
will be preserved at all times and the contents of the re-
cruitment and follow-up forms will not be disclosed to
any third party. The data collected in the study corre-
sponding to a patient will be recorded anonymously.
Ethical aspects
This study will be conducted according to globally
accepted standards of good clinical practice (as defined
in the ICH E6 Guideline for Good Clinical Practice,1 May 1996), in agreement with the Declaration of
Helsinki and in keeping with local regulations. Study
investigators will ensure that all persons assisting with
the trial are adequately qualified, informed about the
protocol, any amendments to the protocol, the study
treatments, and their trial-related duties and functions.
The coordinating centre will maintain a list of sub-
investigators and other appropriately qualified persons
involved in the study. Before being enrolled in the study,
subjects will consent to participate after the nature, scope,
and possible consequences of the clinical trial have been
explained in a form understandable to them. An informed
consent document that includes both information about
the study and the consent form will be given to parti-
cipants. This document will contain all the elements
required by the ICH E6 Guideline for Good Clinical
Practice and any additional elements required by local
regulations. The document will be in a language under-
standable to the participants and will specify who in-
formed the subject. The person who informs the subject
will be a physician. After reading the informed consent
document, the subject, or his/her legal representative,
must give consent in writing. The subject’s consent must
be confirmed at the time of consent by the personally
dated signature of the subject and by the personally dated
signature of the person conducting the informed consent
discussion.
Ethical approval document
The study has been approved by the Ethics Committee
in Verona (coordinating centre) on May 6th 2009
(EUDRACT number 2009-011409-17.
According to the ICH E6 Guideline for Good Clinical
Practice, subjects who will be enrolled in the trial with
the consent of the subjects’ legally acceptable repre-
sentative will be informed about the trial to the extent
compatible with the subjects’ understanding and, if ca-
pable, the subject will be asked to sign and personally
date the written informed consent.
Discussion
The results of this study should indicate whether lithium
treatment is associated with lower risk of completed
suicide and DSH in adult patients with treatment resis-
tant unipolar depression, who recently attempted sui-
cide. At present, evidence is lacking to indicate the most
effective forms of pharmacological treatment for de-
pressed patients with recent history of DSH. To answer
this question is an important clinical issue, given the size
of the DSH population and the risks of subsequent self-
harm, including suicide. To our knowledge, this is the
first study that will prospectively identify suicidal beha-
viour as an outcome measure and systematically assess it
in a randomised design, recruiting a well-characterised
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resistant major depression, with a high risk for suicidal be-
haviour. Moreover, as most meta-analyses of randomised
clinical trials have not detected a reduction in number of
suicides or suicide attempts in studies of antidepressants
or anticonvulsants for mood disorders [24], the prospect
of an agent with suicide-preventive properties is bound to
have an enormous impact on the development of treat-
ment strategies and clinical guidelines [25].
Designing our study, we aimed at being as close as
possible to the real-world clinical setting. The recruiting
centres will all be community based psychiatric services,
where patients are not selected by diagnosis and are a
representative subgroup of the general population. Even
though this may enhance the external validity of the
study and the generalisability of its findings, the hetero-
geneity of patient population might be an issue. High
rate of DSH is usually found in patients with personality
disorders (most of all, borderline disorder). This has
clinical implications because patients with Axis II dis-
order comorbidity are clinically different from patients
with major depression alone and borderline personality
disorder can confer additional risk for suicidal ideation
and DSH [26]. For this reason we stratified the rando-
misation, in order to have an equal distribution of treat-
ment regimens in the two subgroups.
We are aware that to have standard care as compari-
son intervention may cause additional heterogeneity, as
standard care may probably vary from centre to centre.
Variability in standard aftercare of DSH patients in dif-
ferent regions (even though belonging to the same coun-
try, that is, Italy) may influence the relative effectiveness
of experimental interventions in particular settings. In
the final publication we will report all details of the
standard care, as it is provided by clinicians who will
prospectively collect precise data about the nature of the
treatments patients will receive.
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